18454684. CHIMERIC ANTIGEN RECEPTORS THAT BIND PREFERENTIALLY EXPRESSED ANTIGEN IN MELANOMA (PRAME)/HLA-A2 TO TREAT CANCER simplified abstract (Fred Hutchinson Cancer Center)
Contents
- 1 CHIMERIC ANTIGEN RECEPTORS THAT BIND PREFERENTIALLY EXPRESSED ANTIGEN IN MELANOMA (PRAME)/HLA-A2 TO TREAT CANCER
- 1.1 Organization Name
- 1.2 Inventor(s)
- 1.3 CHIMERIC ANTIGEN RECEPTORS THAT BIND PREFERENTIALLY EXPRESSED ANTIGEN IN MELANOMA (PRAME)/HLA-A2 TO TREAT CANCER - A simplified explanation of the abstract
- 1.4 Simplified Explanation
- 1.5 Potential Applications
- 1.6 Problems Solved
- 1.7 Benefits
- 1.8 Potential Commercial Applications
- 1.9 Possible Prior Art
- 1.10 How does the CAR specifically target PRAME/HLA-A2 expressing cancer cells?
- 1.11 What are the potential challenges or limitations of using this technology in clinical settings?
- 1.12 Original Abstract Submitted
CHIMERIC ANTIGEN RECEPTORS THAT BIND PREFERENTIALLY EXPRESSED ANTIGEN IN MELANOMA (PRAME)/HLA-A2 TO TREAT CANCER
Organization Name
Inventor(s)
Soheil Meshinchi of Seattle WA (US)
Danielle Kirkey of Seattle WA (US)
Anisha Loeb of Seattle WA (US)
CHIMERIC ANTIGEN RECEPTORS THAT BIND PREFERENTIALLY EXPRESSED ANTIGEN IN MELANOMA (PRAME)/HLA-A2 TO TREAT CANCER - A simplified explanation of the abstract
This abstract first appeared for US patent application 18454684 titled 'CHIMERIC ANTIGEN RECEPTORS THAT BIND PREFERENTIALLY EXPRESSED ANTIGEN IN MELANOMA (PRAME)/HLA-A2 TO TREAT CANCER
Simplified Explanation
The patent application discloses chimeric antigen receptors (CAR) that specifically bind to Preferentially Expressed Antigen in Melanoma (PRAME) ALY/HLA-A2, which can be used to treat PRAME/HLA-A2 expressing cancers such as certain forms of acute myeloid leukemia.
- The CAR binds to PRAME/HLA-A2, targeting cancer cells expressing this specific antigen.
- The technology can be applied to t(8;21), Inv(16), and KMT2A-r forms of acute myeloid leukemia.
- The innovation provides a targeted approach to cancer treatment, potentially improving efficacy and reducing side effects compared to traditional therapies.
Potential Applications
The technology can be applied in the treatment of PRAME/HLA-A2 expressing cancers, particularly in certain forms of acute myeloid leukemia.
Problems Solved
The technology addresses the need for targeted therapies in cancer treatment, specifically targeting cancer cells expressing PRAME/HLA-A2.
Benefits
The use of CAR technology targeting PRAME/HLA-A2 can potentially improve treatment outcomes, reduce side effects, and provide a more targeted approach to cancer therapy.
Potential Commercial Applications
The technology has potential applications in the development of CAR T-cell therapies for PRAME/HLA-A2 expressing cancers, which could be valuable in the biopharmaceutical industry.
Possible Prior Art
Prior art may include other CAR technologies targeting specific antigens in cancer cells, as well as previous research on PRAME expression in melanoma and other cancers.
Unanswered Questions
How does the CAR specifically target PRAME/HLA-A2 expressing cancer cells?
The mechanism by which the CAR binds to PRAME/HLA-A2 and distinguishes cancer cells from normal cells is not fully explained in the abstract.
What are the potential challenges or limitations of using this technology in clinical settings?
The abstract does not address any potential obstacles or limitations that may arise when translating this technology from the laboratory to clinical applications.
Original Abstract Submitted
Chimeric antigen receptors (CAR) that bind Preferentially Expressed Antigen in Melanoma (PRAME) ALY(SEQ ID NO: 94)/HLA-A2 are disclosed. The CAR can be used to treat PRAME/HLA-A2 expressing cancers such as the t(8;21), Inv(16), and KMT2A-r forms of acute myeloid leukemia (AML).
